Age related medical conditions account for over 60% of all loss of human life

Selvedge Venture invests into founders and start ups with a mission to allieviate the titanic healthcare burden caused by age-related medical conditions. We invest into Pre-Seed, Seed and Series A ready companies across deep technology in life sciences and healthcare

We focus on three age related medical conditions

Metabolic Syndrome (Cardiovascular Disease, Diabetes, Fatty Liver Disease and Obesity), Cancer and Neurodegenerative Diseases. Each of these conditions accounts for a huge burden of both excess deaths and healthcare spend. We invest into mission driven start ups developing technologies to create, curate and/or exploit novel healthcare and life sciences data related to these conditions

Leveraging Biotechnology, Machine Learning Tools and Integrated Data Assets

Selvedge Venture’s core expertise is at the intersection of Biotechnology and Digital Technologies. We believe in a data-centric future with the recent advances in the state of the art of both of these technologies, which will provide a platform to shape healthcare and life sciences for many years to come

FUTURE-PROOF IMPACT INVESTING

Venture Capital is the only asset class where the asset chooses the manager - and not the other way around

We work closely with our founders and our portfolio companies as active managers of our portfolio. We invest both our time and capital with conviction

Current Metabolic Syndrome Patient Figures

Diabetes*

*million

0
US
0
China
0
Mexico

NAFLD/NASH/Cirrhosis*

* million

0
US
0
China

Cardiovascular Disease*

* million

0
US
0
EU

Obesity*

* million

0
US
0
Brazil

Data Sources

US (all disease areas)

American Heart Association: 2021 Heart Disease and Stroke Statistics Update Fact Sheet

Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association

American Diabetes Association: Statistics About Diabetes

Diabetes 2030: Insights from Yesterday, Today, and Future Trends

CDC: Obesity is a common, serious, and costly disease

GWU School of Public Health & Health Services: The Cost of Obesity

Science Direct: Predicting obesity rate and obesity-related healthcare costs using data analytics 

Journal of Clinical Gastroenterology: The Epidemiology of Cirrhosis in the United States

NCBI: Clinical epidemiology and disease burden of nonalcoholic fatty liver disease

Nature Reviews: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

China (Diabetes & NAFLD/NASH/Cirrhosis)

National Center for Biotechnology Information (NCBI): Type 2 diabetes epidemic in East Asia: a 35–year systematic trend analysis

BMJ: Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study

NIH-National Library of Medicine: Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030

EU (CVD)

European Society of Cardiology: Cardiovascular Disease Statistics 2019

European Society of Cardiology:About Cardiovascular Disease in ESC Member Countries

Eurostat: Cardiovascular Diseases Statistics

Brazil (Obesity)

World Obesity Day Press Release: New figures indicate 2.7 billion adults worldwide will be overweight by 2025

Mexico (Diabetes)

Diabetes Research and Clinical Practice

International Diabetes Federation